Karmanos Cancer Institute Partners with Hibiscus to Advance Cancer Treatments

The Barbara Ann Karmanos Cancer Institute announced a partnership with Hibiscus BioVentures to advance cancer treatments. // Courtesy of the Karmanos Cancer Institute

The Barbara Ann Karmanos Cancer Institute in Detroit and Hibiscus BioVentures, which helps build patient-focused businesses around transformative technologies, today announced a partnership agreement to advance cancer treatments.

The partnership between Karmanos and Hibiscus’ venture capital studio, Hibiscus BioTechnology, aims to leverage the combined resources of the two organizations to develop innovative therapies for the treatment of cancer. Karmanos is one of 51 cancer centers nationwide designated by the National Cancer Institute (NCI).

“We are excited to advance this patient-centric approach by leveraging Karmanos’ highly respected development resources,” said Chris Jeffers, CEO of Hibiscus BioTechnology. “As translational and clinical research partners, this collaboration is focused on combining the programs, capabilities and infrastructure of Hibiscus Biotechnology’s studio companies with Karmanos’ vast clinical research and development resources to advance cancer therapies and addressing unmet patient needs. “

The Hibiscus BioTechnology Studio companies each have financial and executive advice and operational support to advance a wide range of science and technology development programs and address unmet patient needs.

The collaboration with Karmanos will provide emerging companies Hibiscus BioTechnology Studio with clinical resources, including access to laboratories and research, scientific and thought leadership, clinical development strategy and access to the Karmanos hospital network to advance more early cancer care.

“Working with emerging companies to bring innovation to the clinic is key to helping bring new cancer therapies closer to patients,” says Dr Elisabeth Heath, Associate Director of the Center for Translational Sciences and Head of the Multidisciplinary Team of Genitourinary Oncology at Wayne State University and the Barbara Ann Karmanos Cancer Institute. “We believe that the combined resources and mission shared by Karmanos and Hibiscus will bring new hope and new tools to cancer treatment.”

The Barbara Ann Karmanos Cancer Institute is a leader in transformative cancer care, research and education. As a member of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan and operates 15 network sites that provide cutting-edge cancer care and clinical trials. Karmanos is recognized by the National Cancer Institute as one of the best cancer centers in the country.

Learn more about Karmanos Cancer Institute at karmanos.org.

Hibiscus BioTechnology is a venture capital studio focused on building “studio companies” based on innovative technologies, engages in the process of building new companies by securing rights to technologies with the promise of supporting programs development that can improve human health.

Technologies, products and business models are typically selected and designed to achieve proof of concept or significant clinical shift within one to three years, representing significant potential value creation.

Hibiscus BioVentures (Hibiscus) helps advance patient care by supporting the development of commercially viable therapies by building patient-centric businesses around transformative technologies. Hibiscus has “Both Sides of the House,” a venture capital studio focused on building businesses from scratch and a venture capital firm focused on investing in promising biotech start-ups.

Hibiscus says it builds and invests in biotech companies and is led by a team of industry experts who can provide the resources to successfully develop new therapies that address unmet patient needs.

For more information on Hibiscus Biotechnology and Hibiscus BioVentures, visit hibiscusbio.com.


Source link

Comments are closed.